大剂量阿托伐他汀治疗急性脑梗死的临床有效性  

The Clinical Effectiveness of High-dose Atorvastatin in the Treatment of Acute Cerebral Infarction

作　　者：郭德刚 张文静 GUO Degang;ZHANG Wenjing(Emergency Department,Liaocheng Third People's Hospital,Liaocheng,Shandong Province,252000 China)

机构地区：[1]聊城市第三人民医院急诊科,山东聊城252000

出　　处：《系统医学》2022年第3期72-75,共4页Systems Medicine

摘　　要：目的针对急性脑梗死应用大剂量阿托伐他汀治疗产生的临床疗效展开研究与分析。方法随机选取2019年8月—2021年3月收治的92例急性脑梗死患者作为研究对象,选用随机数表法将其分为研究组、对照组,每组46例。研究组接受大剂量阿托伐他汀治疗,对照组接受常规剂量阿托伐他汀治疗,对两组治疗效果展开研究与分析。结果研究组治疗后白细胞介素(IL-6)水平(5.91±1.20)pg/mL,超敏C反应蛋白(hs-CRP)水平(3.11±0.89)mg/L,基质金属蛋白酶(MMP-9)水平(322.58±50.46)μg/L低于对照组(11.80±4.32)pg/mL、(5.32±1.10)mg/L、(587.15±63.57)μg/L,差异有统计学意义(t=8.909、10.593、22.108,P<0.05);研究组治疗后总胆固醇(TC)水平(4.89±0.26)mmol/L,三酰甘油(TG)水平(1.80±0.63)mmol/L,低密度脂蛋白胆固醇(LDL-C)水平(2.50±0.37)mmol/L低于对照组(5.38±0.41)、(2.17±0.46)、(2.79±0.61)mmol/L,差异有统计学意义(t=6.845、3.216、2.756、P<0.05);高密度脂蛋白胆固醇(HDL-C)水平(1.87±0.41)mmol/L高于对照组(1.63±0.28)mmol/L,差异有统计学意义(t=3.278,P<0.05);研究组治疗后中膜厚度(IMT)(0.86±0.26)mm,斑块面积(14.21±2.08)mm^(2)均低于对照组(1.02±0.31)mm、(16.23±3.51)mm2,差异有统计学意义(t=2.682、3.357、P<0.05);研究组不良反应发生率2.17%与对照组6.52%比较,差异无统计学意义(χ^(2)=0.261,P>0.05)。结论利用大剂量阿托伐他汀对急性脑梗死患者实施临床医治,可以显著提升其诊疗效果,不良反应少,安全性好,适合推广使用。Objective To study and analyze the clinical efficacy of high-dose atorvastatin in the treatment of acute cerebral infarction.Methods 92 patients with acute cerebral infarction treated from August 2019 to March 2021 were randomly selected as the research object,and they were divided into the study group and the control group by the random number table method,with 46 cases in each group.The study group received high-dose atorvastatin treatment,and the control group received conventional dose atorvastatin treatment.The therapeutic effects of the two groups were studied and analyzed.Results After treatment,the level of IL-6 in the study group was(5.91±1.20)pg/mL,the level of hs-CRP(3.11±0.89)mg/L,and the level of MMP-9(322.58±50.46)μg/L,which were lower than the control group(11.80±4.32)pg/mL,(5.32±1.10)mg/L,(587.15±63.57)μg/L,the difference was statistically significant(t=8.909,10.593,22.108,P<0.05);after treatment in the study group,TC levels were(4.89±0.26)mmol/L,TG levels(1.80±0.63)mmol/L,and LDL-C levels(2.50±0.37)mmol/L,which were lower than the control group(5.38±0.41)mmol/L,(2.17±0.46)mmol/L,(2.79±0.61)mmol/L,the difference was statistically significant(t=6.845,3.216,2.756,P<0.05);the level of HDL-C(1.87±0.41)mmol/L was higher than that of the control group(1.63±0.28)mmol/L,the difference was statistically significant(t=3.278,P<0.05);after treatment,IMT(0.86±0.26)mm and plaque area(14.21±2.08)mm2 in the study group were lower than those in the control group(1.02±0.31)mm,(16.23±3.51)mm^(2),the difference was statistically significant(t=2.682,3.357,P<0.05);there was no statistically significant difference in the incidence of adverse reactions between 2.17%in the study group and 6.52%in the control group(χ^(2)=0.261,P>0.05).Conclusion The use of high-dose atorvastatin for clinical treatment of patients with acute cerebral infarction can significantly improve the diagnosis and treatment effect,with few adverse reactions and good safety.It is suitable for promotion and use.

关 键 词：大剂量 阿托伐他汀 急性脑梗死 临床有效性 

分 类 号：R59[医药卫生—内科学]